Latest Regulatory Filings News

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Impact Minerals Limited reported a solid cash position of A$3.75 million at quarter-end, supported by a recent equity raise that extends its funding runway to nearly four quarters despite ongoing exploration expenditures.

Quickstep Holdings reported a $5.8 million net operating cash outflow in Q3 FY25 but bolstered liquidity by securing $6.6 million in customer advances and implementing cost controls.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Arafura Rare Earths has marked a pivotal quarter with a A$200 million cornerstone equity commitment for its Nolans Project, alongside binding offtake agreements securing two-thirds of its NdPr oxide target amid rising rare earth demand and geopolitical tensions.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Antipa Minerals has consolidated its Paterson Province tenements into the expansive Minyari Project, resumed full ownership of Wilki and Paterson Projects following partner withdrawals, and launched a major drilling campaign targeting resource growth and new discoveries.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.